Human Clusterin DuoSet ELISA

High μg/mL concentrations of Clusterin circulate predominantly as a component of high density lipoprotein particles, and these are internalized and degraded through interactions with LRP-2/Megalin (10, 11). The ability of Clusterin to bind and neutralize non-oxidatively modified LDL reduces cytotoxicity in atherosclerotic plaques (12). The chaperone function of Clusterin helps to reduce the accumulation of beta-amyloid fibrils and damage due to amyloid plaques in Alzheimer's disease (13). An alternately spliced 50 kDa isoform of human Clusterin (nCLU) remains intracellular and is neither glycosylated nor cleaved into alpha and beta chains (5, 14). Cellular exposure to ionizing radiation promotes the translocation of nCLU to the nucleus where it interacts with Ku70 and promotes apoptosis (5, 14). This function contrasts with the cytoprotective effect of secreted Clusterin (15). During tumor progression, nCLU is down regulated while the secreted form is upregulated and may be aberrantly glycosylated (14, 16, 17). Increased circulating levels of Clusterin enhance tumor aggressiveness by inhibiting apoptosis and by promoting the epithelial to mesenchymal transition (18-20).